
    
      Total study duration is up to 30 weeks, including a screening period consisting of a
      screening phase of up to 2 weeks and a 2-week single-blind placebo run-in phase, a 24-week
      double-blind treatment period, and a 2-week post-treatment follow-up visit period to collect
      safety information.
    
  